COVID-19 and psoriasis: Should we fear for patients treated with biologics?

39Citations
Citations of this article
172Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The new coronavirus pandemic poses question and challenges for dermatologists. One of question is if psoriasis patients treated with immunomodulating and immunosuppressive drugs have to discontinue their treatment in the midst of fears for the infection and its consequences. One of the challenges is how can we support our patients in this critical time. Previous coronaviruses outbreaks reports, current published evidences on pathogenesis and on clinical reports of COVID infection in immunosuppressed patients are used to make a scientifically based decision.

Cite

CITATION STYLE

APA

Amerio, P., Prignano, F., Giuliani, F., & Gualdi, G. (2020, July 1). COVID-19 and psoriasis: Should we fear for patients treated with biologics? Dermatologic Therapy. Blackwell Publishing Inc. https://doi.org/10.1111/dth.13434

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free